Background Daclatasvir and asunaprevir combination therapy has shown a high virological response for chronic genotype 1 hepatitis C virus (HCV)-infected patients. However, the safety and efficacy of the therapy for older patients are unknown. Methods One hundred seventy patients younger than 75 years and 139 patients aged 75 years or older with genotype 1 HCV infection were treated for 24 weeks with daclatasvir plus asunaprevir. Pretreatment drug-resistanceassociated variants at NS5A-L31 and NS5A-Y93 were determined by the Invader assay. Virological response and adverse events according to age were analyzed. Results The sustained virological response (SVR) rate for older patients was similar to that for younger patients (97.1 and 92.4 % respectively). In multivariate regression analysis, prior simeprevir treatment (odds ratio 56.6 for absence; P \ 0.001) was identified as a significant independent predictor of SVR. The SVR rate for patients with pretreatment resistance-associated variants (RAVs) at a low population frequency (less than 25 %) was similar to that for patients with no detectable RAVs. The frequency of adverse events was similar between younger and older patients. All 19 very elderly patients (85 years or older) completed the 24 weeks of treatment and achieved SVR. Conclusions Older patients have a virological response and tolerance of daclatasvir plus asunaprevir therapy similar to those of younger patients. Even though RAVs were detected, virological response similar to that for patients with no detectable RAVs may still be expected for patients with RAVs as long as the population frequency is low.
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Introduction
Chronic hepatitis C virus (HCV) infection affects approximately 180 million individuals worldwide and is a common cause of chronic liver disease and hepatocellular carcinoma in Japan, the USA, and many European countries [1] . In Japan, patients chronically infected with HCV tend to be older and are predominantly infected with HCV genotype 1, both of which impact the response to therapy [2] . Treatment of chronic HCV infection with pegylated interferon (PEG-IFN) and ribavirin elicits a sustained virological response (SVR) in only 40-50 % of treatmentnaïve patients with genotype 1 infections [3, 4] . The SVR rate in this population increased to 62.2-75 % when telaprevir, a selective HCV NS3/4 protease inhibitor, was added to the regimen [5, 6] . Similarly, the SVR rate increased to 72.6-88.6 % when simeprevir, a second-generation protease inhibitor, was added to the regimen [7, 8] . On the other hand, various adverse events are associated with PEG-IFN plus ribavirin therapy, and the addition of telaprevir to PEG-IFN plus ribavirin therapy introduced additional side effects, including anemia, skin disorders, severe rash, and gastrointestinal-tract-related disorders, whereas the addition of the better tolerated simeprevir is associated with hyperbilirubinemia [3] [4] [5] [6] [7] [8] .
Older patients with chronic hepatitis C have a higher risk of liver carcinogenesis [9, 10] , and therefore early HCV eradication is needed for such patients. However, older patients have a lower rate of virological response to interferon-based treatments and are more prone to severe adverse events such as anemia and renal dysfunction than younger patients [2, [11] [12] [13] .
Direct-acting antiviral (DAA) combination therapies may also overcome interferon nonresponsiveness in null responders by increasing antiviral activity. An interferonfree DAA dual therapy with daclatasvir, an NS5A replication complex inhibitor, and asunaprevir, an NS3/4A protease inhibitor, resulted in an improved SVR rate and shorter duration of therapy for genotype 1 HCV infection [14] [15] [16] [17] [18] . The combination treatment was approved in Japan in 2014 [19] . However, the safety and efficacy of daclatasvir plus asunaprevir combination therapy for older patients has not been closely examined.
In the present study, we assessed the safety and the efficacy of the dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Methods

Patients
Three hundred nine patients with chronic genotype 1 HCV infection who were treated with daclatasvir and asunaprevir dual therapy between September 2014 and August 2015 at Hiroshima University Hospital and Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital were enrolled. The inclusion criteria for the study included patients remaining positive for genotype 1 HCV RNA for 6 months. Patients with decompensated cirrhosis were excluded. Cirrhosis was defined either by pretreatment liver biopsy or according to the laboratory algorithm of Ikeda et al. [20] . All participants provided written informed consent for their participation in the study according to the process approved by the ethics committee of each hospital and conforming to the ethical guidelines of the 1975 Declaration of Helsinki.
HCV RNA levels
HCV RNA levels were measured by the COBAS TaqMan HCV test (Roche Diagnostics, Tokyo, Japan). The detection limit for the assay was 1.2 log IU/mL. HCV genotype was determined by sequence determination in the 5 0 nonstructural region of the HCV genome, followed by phylogenetic analysis.
Single nucleotide polymorphism genotyping
Each patient was genotyped for two single nucleotide polymorphisms: ss469415590 in theIFNL4 locus [21, 22] . Samples were genotyped with use of the Illumina HumanHap610-Quad Genotyping BeadChip or the Invader or TaqMan assays as described previously [23] .
Detection of drug-resistant substitutions
The amino acid sequences of NS3-D168, NS5A-L31, and NS5A-Y93 were determined by the Invader assay as described previously [24] . The lower detectable limit for population frequency of the Invader assay is 1 %.
Therapeutic protocol
Patients received 24 weeks of treatment with daclatasvir (Daklinza, Bristol-Myers Squibb, New York NY, USA) at a dosage of 60 mg once daily and asunaprevir (Sunvepra, Bristol-Myers Squibb) at a dosage of 200 mg twice daily. Completion of the treatment was defined as completion of 24 weeks of treatment with both daclatasvir and asunaprevir. We discontinued treatment in the event of viral breakthrough or when adverse events made continuation of treatment difficult.
Efficacy of the treatment
Serum HCV RNA levels were measured before the start of treatment and every 4 weeks during treatment. End-oftreatment response and SVR were defined as undetectable HCV RNA at the end of treatment and 24 weeks after the end of treatment respectively.
Mann-Whitney U tests were applied to detect significant associations. Univariate and multivariate analyses were used to examine the association between treatment outcome and the values of other factors, with P \ 0.05 as the criterion for inclusion in the multivariate model. All statistical tests were two-sided, and P \ 0.05 was considered significant. All statistical analyses were performed with PASW Statistics 22 (SPSS, Chicago, IL, USA).
Results
Baseline patient characteristics
Baseline characteristics of the 309 patients are shown in Table 1 . The median age was 74 years. Patients were grouped according to age (younger patients, younger than 75 years, n = 170; older patients, 75 years or older, n = 139). The hemoglobin, alanine aminotransferase, and c-glutamyl transpeptidase levels and the estimated glomerular filtration rates were significantly lower in older patients than in younger patients. Older patients had significantly higher frequencies of IFNL4 genotype TT/TT, a history of interferon therapy, and a history of telaprevir therapy than younger patients. Pretreatment NS5A-L31/ NS5A-Y93 drug-resistance-associated variants were detected at similar frequencies in the two groups.
Virological response by age
Serum HCV RNA became undetectable at week 8 of treatment in all patients. During the treatment, viral breakthrough developed in ten younger patients and two older patients, and end-of-treatment response was achieved in 94.1 % of younger patients and 98.6 % of older patients (Fig. 1) . After the end of therapy, serum HCV relapse 
Predictive factors associated with SVR
In all patients, significant univariate predictors for SVR included body height, a history of simeprevir treatment, total cholesterol level, and treatment discontinuation ( Table 2) . Multivariate logistic regression analysis identified a history of simeprevir treatment (odds ratio 56.6 for absence; P \ 0.001) as an independent predictor for SVR. Although the SVR rate was 96.3 % (289 of 300 cases) in patients without prior simeprevir treatment, it was only 33.3 % (three of nine cases) in patients with a history of simeprevir triple therapy. NS3-D168 resistance-associated variants (RAVs) were determined by the Invader assay for eight of the nine patients who underwent simeprevir therapy prior to daclatasvir plus asunaprevir treatment, and NS3-D168E/V RAVs were detected in three of the patients. Among these three patients, one patient achieved SVR, whereas the other two failed to respond to the treatment. Among the five patients who did not have NS3-D168 RAVs, one patient achieved SVR and treatment failed in the remaining four patients. The SVR rate was 83.3 % (5 of 6 cases) in patients who discontinued treatment and 98.6 % (287 of 291 cases) in patients who completed treatment. IFNL4 genotype was not associated with SVR. Patients with chronic hepatitis and liver cirrhosis showed similar SVR rates (95.0 and 93.6 % respectively).
Treatment response for patients with pretreatment NS5A RAVs
The population frequencies of pretreatment NS5A-L31 and NS5A-Y93 RAVs were determined in 147 younger patients and 116 older patients by the Invader assay [24] . Although RAVs were detected in 36 patients (6 patients with L31M/ V, 29 patients with Y93H, and 1 patient with L31V and Y93H), the population frequencies of these mutations were relatively low. The SVR rates for patients with no detectable pretreatment NS5A RAVs (less than 1 %) were 95.4 % (124 of 130 patients) and 98.9 % (96 of 97 patients) in younger patients and older patients respectively (Fig. 2) . When patients with high and low NS5A RAV population frequencies were compared by age, all patients with RAVs at a low frequency (approximately 1-25 %) achieved SVR, whereas among patients with RAVs at a high frequency (greater than approximately 25 %) 71.4 % of younger patients (5 of 7 patients) and 90.9 % of older patients (10 of 11 patients) achieved SVR. The patient with the L31V and Y93H double mutation (1-25 % L31V and more than 25 % Y93H) achieved SVR.
Adverse events
Adverse events were evaluated according to Common Terminology Criteria for Adverse Events version 4.0. The most frequent adverse event was a flulike syndrome, which developed in 140 patients (45.3 %), all cases of which were grade 1 ( Table 3 ). The second most frequent adverse event was aminotransferase level elevation, which developed in 117 patients [grade 1, 99 patients (32.0 %); grade 2, 11 patients (3.6 %), and grade 3, 7 patients (2.3 %)]. The frequencies of adverse events were similar between younger and older patients.
Treatment was discontinued in four younger patients (2.3 %) because of cough at 5 weeks, aminotransferase level elevation at 12 weeks (two patients), and hepatic encephalopathy at 13 weeks, and treatment was discontinued in two older patients (1.4 %) because of liver dysfunction at 4 weeks and minimal change nephrotic syndrome at 21 weeks. Although HCV relapse occurred in one older patient (treatment discontinuation at 21 weeks), the remaining five patients achieved SVR.
Discussion
Elimination of HCV after interferon therapy significantly reduces the risk of hepatocellular carcinoma and death in older patients [25] ; however, older patients compared with younger patients have a lower virological response to interferon-based treatment [2, [11] [12] [13] . In the present study, interferon-free daclatasvir plus asunaprevir treatment resulted in SVR rates of 92.4 and 97.1 % for younger and older patients respectively. In contrast to interferon-based therapy, the virological response to daclatasvir plus asunaprevir treatment in older patients was similar to that in younger patients.
Patients with NS5A-L31 and/or NS5A-Y93 RAVs are likelier to fail to respond to daclatasvir and asunaprevir combination treatment than patients with the wild type [26] . In a phase 3 clinical trial in Japan, the SVR rate for patients who had NS5A-L31 and/or NS5A-Y93 amino acid substitutions (determined by direct sequencing analysis) was 41 % after 24 weeks of daclatasvir plus asunaprevir combination therapy [19, 27] . Pretreatment NS5A-L31 and/or NS5A-Y93 amino acid substitutions were detected in 36 patients by the Invader assay in the present study; however, the populations of these RAVs were relatively low. Although pretreatment RAVs were detected, all patients with a low frequency of RAVs (approximately 1-25 %) achieved SVR. In contrast, the SVR rates slightly decreased in patients with a high frequency of RAVs (more than 25 %); however, the SVR rate for older patients with a high frequency of RAVs was similar to that in younger patients (90.9 and 71.4 % respectively). These results indicate that even though NS5A-L31 and NS5A-Y93 RAVs were detected, a virological response similar to that of patients with no detectable RAVs may still be expected as daclatasvir plus asunaprevir treatment is administered exclusively to both younger and older patients with low populations of RAVs. The SVR rate for patients with an RAV frequency of 25 % or more in the present study was higher than that in the Japanese phase 3 clinical study [19] . The reason is unclear; however, the low frequency of treatment discontinuation in this study may have contributed.
Patients with a history of simeprevir and PEG-IFN plus ribavirin treatment showed a significantly lower virological response rate to daclatasvir and asunaprevir treatment compared with those without prior DAA treatment. NS3-D168 RAVs were detected in patients who had previously experienced simeprevir and PEG-IFN plus ribavirin treatment failure [7, 8] . However, NS3/4A-protease-resistant HCV variants have been reported to show reduced fitness, as estimated by viral replicative ability and production of infectious progeny [28, 29] ; therefore, the frequency of treatment-emergent simeprevir-induced RAVs gradually declined and became undetectable over time as measured by deep sequence analysis [30] . In the present study, although five patients with prior simeprevir treatment had wild-type NS3-D168, four of these patients failed to respond to daclatasvir plus asunaprevir treatment. These results indicate that although NS3-D168 RAVs were not detected, simeprevir and PEG-IFN plus ribavirin treatment failure is likely to lead to failure of daclatasvir plus asunaprevir treatment as well. Thus, DAA treatment with an NS5A inhibitor and an NS5B polymerase inhibitor is recommended for such patients instead.
Single nucleotide polymorphism ss469415590 in the IFNL4 gene is strongly associated with HCV clearance both through the innate immune response and in response to PEG-IFN plus ribavirin therapy [21, 22] . In the present study, the SVR rates in patients with the IFNL4 TT/TT genotype were similar to those in patients with the IFNL4 TT/DG or IFNL4 DG/DG genotype for both younger patients [93.2 % (69 of 74 patients) and 90.8 % (69 of 76 patients) respectively] and older patients [97.7 % (85 of 87 patients) and 94.6 % (35 of 37 patients) respectively]. Therefore, it is thought that daclatasvir plus asunaprevir treatment may be particularly effective for patients who have a low susceptibility to or poor tolerance of interferon, including older patients and patients with the IFNL4 TT/ DG genotype or IFNL4 DG/DG genotype.
Interferon-based treatment is associated with more frequent and adverser events, and treatment discontinuation is frequently needed, especially in older patients [2, [11] [12] [13] . In contrast to interferon-based therapy, the rate of treatment discontinuation for daclatasvir plus asunaprevir therapy due to adverse events was comparatively low [six patients (1.9 %) in the present study]. The frequencies of adverse events and treatment discontinuation in older patients were similar to those in younger patients, indicating that the safety of daclatasvir and asunaprevir combination therapy for older patients is relatively high. In the present study, 19 very elderly patients (85 years or older) patients were included. These very elderly patients showed a frequency of adverse events similar to that of younger patients. Moreover, the 24 weeks of treatment was completed and SVR was achieved in all 19 of these patients. Therefore, this combination therapy seems to be a treatment option even for very elderly patients.
In conclusion, older patients have a virological response and tolerance of daclatasvir and asunaprevir combination therapy similar to those of younger patients. Even though NS5A-L31 and NS5A-Y93 RAVs were detected, a high SVR may still be anticipated for patients with low population frequencies of RAVs. The combination therapy should be considered as a safe and effective treatment option for older patients with genotype 1 HCV infection.
